(NASDAQ: TNDM) Tandem Diabetes Care's forecast annual revenue growth rate of 10% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Tandem Diabetes Care's revenue in 2026 is $1,007,001,000.On average, 27 Wall Street analysts forecast TNDM's revenue for 2026 to be $76,345,456,234, with the lowest TNDM revenue forecast at $70,921,267,514, and the highest TNDM revenue forecast at $80,956,016,646. On average, 24 Wall Street analysts forecast TNDM's revenue for 2027 to be $83,396,901,570, with the lowest TNDM revenue forecast at $76,481,060,952, and the highest TNDM revenue forecast at $88,549,880,854.
In 2028, TNDM is forecast to generate $91,058,568,137 in revenue, with the lowest revenue forecast at $82,515,470,903 and the highest revenue forecast at $100,686,503,115.